Ezabenlimab, PD-1 antibody
Ezabenlimab, PD-1 antibody
Search
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
VSV-GP
VSV-GP
Breathing hope: fighting the lung disease pulmonary fibrosis
The animation and accompanying article aims to draw attention to and raise awareness about pulmonary fibrosis, a disease often misdiagnosed an overlooked.
BULTAVO 3
Indicated for bluetongue disease serotype 3 in sheep and cattle
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Fremont
Upstream process development in a high throughput automated bioreactor system.
Phase 1 start of treatment for Geographic Atrophy patients
Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)
Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Veterinarians: caught between excellence and exhaustion
Many children dream of becoming a veterinarian. What happens when that dream comes true?
Women in STEM: Passion for science
Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.
Boehringer Ingelheim Advances Oncology Research
Boehringer Ingelheim Advances Its Oncology Research Program Through Innovative Partnerships
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
SIRPα antagonist
SIRPα antagonist
Generalized pustular psoriasis: Unmet needs
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
Reduction of Salmonella in swine after vaccination
Authorities acknowledge reduction of Salmonella after vaccination with Enterisol® Ileitis
The geography of pet parasites is changing
Climate change facilitates new pet parasites way beyond ticks and flea bites in dogs and cats
European Commission decision for Pradaxa® in children with VTE
Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved